2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Relapsing-Remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-Remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-Remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis BCD-281, Ocrelizumab - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Recruiting | Biocad | 292 | 2025-11-01 | 2026-01-06 |
Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Recurrence (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
ocrelizumab (2) · Dimethyl Fumarate (1) · Glatiramer Acetate (1) · Interferon-beta (1) · Rituximab (1) · ofatumumab (1) · teriflunomide (1)
Biocad (1) · University Hospital, Montpellier (1)
France (1) · Russia (1)